Rapcabtagene autoleucel is a gene-modified cell therapy commercialized by Novart...
Public health experts are anticipating a changing discourse following RFK Jr’s a...
AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampli...
RLYB-116 is a fusion protein commercialized by Rallybio, with a leading Phase I ...
ORIC-944 is a small molecule commercialized by ORIC Pharmaceuticals, with a lead...
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeuti...
The results from the Phase III trial found the LDL-C treatment to be well tolera...
The EMA has validated Chiesi Global Rare Diseases and Protalix’s submission to u...
The respiratory syncytial virus (RSV) prophylaxis market across the eight major ...
An improved price discount and new evidence from Santhera has changed NICE’s tun...
Seres Therapeutics has received US FDA breakthrough therapy designation for its ...
The US FDA has accepted a submission from GSK to review a new indication of Nuca...
Lilly’s investment and the UK government’s strategic support for life sciences a...
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) pa...
InCarda Therapeutics has announced the appointment of Dr Myles Greenberg as its ...
While 88.1% of patients completed one cycle, patient adherence beyond the fourth...
